Introduction
============

Cervical cancer is estimated to be the fourth most frequent type of cancer among women worldwide ([@b1-ol-0-0-9104]) and the fourth leading cause of cancer-related mortality ([@b1-ol-0-0-9104]--[@b3-ol-0-0-9104]). Environmental factors, living habits and human papillomavirus (HPV) infection have been linked to the development of cervical cancer ([@b4-ol-0-0-9104]--[@b6-ol-0-0-9104]). Specifically, HPV infection is considered to be one of the most important causal factors related to cervical cancer ([@b7-ol-0-0-9104]). However, HPV alone, appears to not be sufficient for the development of cervical cancer ([@b8-ol-0-0-9104]), as only a small amount of HPV-infected women finally develop cervical cancer ([@b3-ol-0-0-9104],[@b9-ol-0-0-9104]).

A number studies have provided evidence of familial clustering of cervical cancer, supporting the existence of genetic effects ([@b10-ol-0-0-9104]--[@b12-ol-0-0-9104]). Moreover, several association studies have demonstrated a number of genetic variants that possibly confer susceptibility to cervical cancer by affecting immune responses, DNA repair or viral cell entry and infection ([@b3-ol-0-0-9104],[@b13-ol-0-0-9104],[@b14-ol-0-0-9104]). However, uncertainty for the effect size of genetic variants, particularly in different ethnic backgrounds still exists, as the results of different genetic studies have been conflicting ([@b13-ol-0-0-9104]).

Recently, Wang *et al*, genotyped 7,140 SNPs across 305 genes that were involved in HPV infection, cell entry and DNA repair, and reported that genes, among which general transcription factor IIH subunit 4 (*GTF2H4*), deoxyuridine triphosphatase (*DUT*), DNA meiotic recombinase 1 (*DMC1*), 2′-5-oligoadenylate synthetase 3 (*OAS3*), sulfatase 1 (*SULF1*), interferon gamma (*IFNG*), transmembrane channel like 6 (*TMC6*) and transmembrane channel like 8 (*TMC8*) were associated with the risk of HPV persistence and cervical pre-cancer/cancer ([@b14-ol-0-0-9104]). The loss of the expression of *DMC1* plays an important role in the development of cancers in human tissues, including cervical cancer lines ([@b15-ol-0-0-9104]). The DUT enzyme influences nucleotide metabolism by producing the immediate precursor of thymidine nucleotides, dUMP, and consequently decreasing the intracellular concentration of dUTP ([@b16-ol-0-0-9104]). As a result, uracil cannot be incorporated into DNA ([@b16-ol-0-0-9104]). SULF1 is a heparin-degrading endosulfatase, which desulfates heparan sulfate proteoglycans (HSPGs) and blocks the binding of growth factors and their receptors, inhibiting as a result, the activation of growth factors and signaling pathways ([@b17-ol-0-0-9104],[@b18-ol-0-0-9104]). OAS3 is induced during viral infection and plays an important role on the antiviral intracellular innate immune response ([@b19-ol-0-0-9104]). GTF2H4 is a general transcription factor that interacts with factors important in carcinogenesis and is involved in processes of DNA repair and transcriptional control ([@b20-ol-0-0-9104]). IFNG is regulatory cytokine, released by lymphocytes, that enhances cellular immune responses via increased T-cell cytotoxicity and natural killer (NK)-cell activity ([@b21-ol-0-0-9104]). The *TMC6* and *TMC8* genes (also referred to as *EVER1* and *EVER2* genes), are known for the development of Epidermodysplasia verruciformis, which is associated with a high sensitivity to HPV infections ([@b22-ol-0-0-9104]). The TMC6 and TMC8 proteins appear to regulate cellular zinc homeostasis in keratinocytes and lymphocyte ([@b23-ol-0-0-9104]).

In a previous analysis in a population from Northern Greece ([@b3-ol-0-0-9104]), we failed to detect a significant effect of two SNPs of the *EVER1/2* gene region (rs2290907 and rs16970849) and the *FAS-670* polymorphism (rs1800682) on precancerous lesions and cervical cancer. This was in contrast to a previous positive study by Castro *et al* ([@b24-ol-0-0-9104]). FAS belongs to the family of tumor necrosis factor (TNF) receptors ([@b25-ol-0-0-9104],[@b26-ol-0-0-9104]). The downregulation of FAS leads to resistance to death signals, a phenomenon that has been observed in cervical cancer ([@b27-ol-0-0-9104]--[@b30-ol-0-0-9104]).

The present study was designed to replicate the findings reported by Wang *et al* ([@b14-ol-0-0-9104]) and Castro *et al* ([@b24-ol-0-0-9104]) in a different, from our previous study ([@b3-ol-0-0-9104]), Greek population of Central Greece. In particular, we examined the effects of 10 SNPs (rs1800682, rs5757133, rs3784621, rs4737999, rs12302655, rs2894054, rs11177074, rs2290907, rs9893818 and \[*FAS, DMC1, DUT, SULF1, OAS3, GTF2H4, IFNG, TMC6* and *TMC8* (2 SNPs)\] on the risk of precancerous lesions and cervical cancer.

Materials and methods
=====================

### Study population

A total of 608 women that had attended the Obstetrics and Gynaecology Clinic of the University Hospital of Larissa, Larissa, Greece participated in this study. The patient group consisted of 316 women with a histopathologically confirmed diagnosis of cervical cancer (n=17) or precancerous lesions, either high grade (CIN2/3, n=100) or persistent low grade (CIN1, n=199). The control group consisted of 292 age-matched women with normal annual cervical cytology screening.

The local Ethics Review Board of the University Hospital of Larissa approved the study protocol. Informed consent was obtained from all individual participants included in the study.

### Isolation of DNA and genotyping

Genomic DNA was extracted from 200 µl of EDTA-anti-coagulated whole blood, using a QIAamp^®^ DNA Blood Mini kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer\'s instructions. SNPs were genotyped with TaqMan allele-specific PCR amplification technology on an ABI PRISM 7900 Sequence Detection System and analyzed with the Sequence Detection Software (SDS 2.1) (both from Applied Biosystems, Foster City, CA, USA) by laboratory personnel blinded to clinical status. In order to assess genotyping reproducibility, initially observed SNP allelic discrimination curves of all genotypes were confirmed by direct DNA sequencing on an ABI PRISM 3100 genetic analyzer (Applied Biosystems).

### Statistical analysis

Hardy-Weinberg equilibrium was examined with the exact test Power calculation analysis performed using the CaTS Power Calculator ([@b31-ol-0-0-9104]). Genotype-disease association analysis was performed with binary logistic regression using the SNPStats platform (<http://bioinfo.iconcologia.net/SNPstats/>) ([@b32-ol-0-0-9104]). Odds ratios (ORs), 95% confidence intervals (CIs) and P-values were calculated assuming the co-dominant (genotypic) model (AA vs. Ab vs. bb) and the recessive (AA + Ab vs. bb) modes of inheritance. Four phenotypic groups were searched for the association with the analyzed SNPs compared to the healthy controls: i) The cervical cancer group; ii) the group of patients with high-grade precancerous lesions (CIN2/3); iii) the group of patients with low-grade precancerous lesions (CIN1); and iv) an overall patient group with abnormal cervical changes (either cervical cancer or any type of precancerous lesions).

Results
=======

The characteristics of the 10 studied SNPs (gene, chromosome, chromosomal position, minor allele and minor allele frequencies) are presented in [Table I](#tI-ol-0-0-9104){ref-type="table"}. The genotype call rate was ≥98.85%. All studied SNPs were found to follow the Hardy-Weinberg equilibrium either in the cases or the controls (exact test, P\>0.01) ([@b33-ol-0-0-9104]). Genotype call rate and P-value (exact test) for HWE, for each SNP, are presented and [Table II](#tII-ol-0-0-9104){ref-type="table"}.

The allelic and genotypic frequencies of the studied SNPs in the control and the overall patient group, as well as in the cervical cancer, high-grade precancerous lesion and low-grade precancerous lesion groups are presented in [Table III](#tIII-ol-0-0-9104){ref-type="table"}. Of note, as regards rs9893818, all successfully genotyped participants (100%) carried the CC genotype, whereas as regards rs12302655, \>99.0% of the participants carried the wild-type genotype.

Power analysis revealed that our study had a statistical power of \>80.0% to detect an genetic association with an OR of 1.78, under the assumption of the multiplicative model, a minor allele frequency of 5% (the lowest in cases for the rs16970849), a type I error level of 0.05, in a sample size consisting of 292 controls and 316 cases (data not shown).

Binary logistic regression analysis demonstrated a significant effect of *SULF1* rs4737999 on the risk of the abnormal cervical changes. In particular, a significant difference was observed between the controls and the overall patient group (low-grade, high-grade and cervical cancer) considering the recessive mode of inheritance (OR, 0.48; 95% CI, 0.24--0.96; P=0.033). Individuals carrying the AA genotype had almost half a risk of having cervical cancer, and low- or high-grade lesions compared to those carrying either the GG or the GA genotypes. Moreover, this effect was even more potent on the risk of low-grade precancerous lesions (OR, 0.36; 95% CI, 0.14--0.92; P=0.042) and (OR, 0.35; 95% CI, 0.14--0.87; P=0.014) in the co-dominant and recessive models, respectively. Carriers of the rs4737999 AA genotype were almost 3-fold less likely of having low-grade lesions compared to carriers of the other genotypes. No other SNP was found to alter the risk of any examined phenotype ([Table IV](#tIV-ol-0-0-9104){ref-type="table"}).

The main mechanism of *SULF1* gene is presented in [Fig. 1](#f1-ol-0-0-9104){ref-type="fig"}. *SULF1* gene encodes the SULF1 protein. SULF1 is a heparin-degrading endosulfatase, which desulfates HSPGs and blocks the binding of growth factors and their receptors. Consequently, it inhibits the activation of growth factor and the signaling pathways.

Discussion
==========

In the present study, we tried to replicate the findings of previous studies regarding the role of SNPs in DNA repair, viral infection and cell entry, and their effects on the risk of cervical cancer and precancerous lesions ([@b14-ol-0-0-9104],[@b24-ol-0-0-9104]). In addition, we re-examined an independent Greek cohort in order to determine the influence of the rs1800682 (*FAS*), rs2290907 (*TMC6*) and rs16970849 (*TMC8*) gene variants ([@b3-ol-0-0-9104]). In the present study, we found that a specific variant of the *SULF1* gene, rs4737999, was associated with a significantly decreased risk of developing precancerous lesions and cervical cancer.

The *SULF1* gene is located at the 8q13.3 region. It encodes the homonymous protein, a heparin-degrading endosulfatase, which desulfates HSPGs and blocks the binding of growth factors and their receptors and as a result it inhibits the activation of growth factor and the signaling pathways ([Fig. 1](#f1-ol-0-0-9104){ref-type="fig"}) ([@b17-ol-0-0-9104],[@b18-ol-0-0-9104]). The expression of *SULF1* appears to be stable in normal tissues, whereas it is downregulated in several tumor cells ([@b34-ol-0-0-9104]). Moreover, the proliferation and migration of tumor cells can be inhibited by the re-expression of the *SULF1* gene ([@b35-ol-0-0-9104]).

In the study by Wang *et al* ([@b14-ol-0-0-9104]), the *SULF1* gene reached a statistically significant threshold for the CIN3/Cancer group compared to the controls (P=0.0030). Moreover, the *SULF1* gene was also associated with HPV persistence (P=0.005). Additionally, according to SNP-Based association analysis, when the CIN3/Cancer group was compared to the control group, 3 out of the 77 examined *SULF1* SNPs (rs4737999, rs4284050 and rs10108002) achieved statistical significance (P-value trend \<0.05). In this analysis of Wang *et al*, the strongest association was reported for the rs4737999; this polymorphism also was associated with precancerous lesions and cervical cancer in the present study.

A number of SNPs of the *SULF1* gene have been found to influence the risk of cancer. The AA genotype of r3802278, a SNP located in the 3′-untranslated region (3′-UTR) of the *SULF1* gene, was found to play a protective role against breast cancer ([@b36-ol-0-0-9104]). Moreover, rs2623047, a 5′-upstream gene variant in *SULF1*, has been associated with an increased risk of breast cancer, as well as with an earlier age of onset and the survival of ovarian cancer ([@b37-ol-0-0-9104]). Finally, rs6990375, a 3′ prime UTR variant, has been associated with earlier age of ovarian cancer ([@b38-ol-0-0-9104]). The SNP rs4737999, that reached a statistically significant threshold in the present study, is an intronic non-coding variant located between exons 13 and 14. Therefore, the *SULF1* gene may represent an important locus linked to tumorigenesis, as SNPs located in the 5′-upstream region, in the 3′-UTR region or even in the middle of the gene have been found to alter the risk of cancer.

A number of studies have reported that the *FAS-670* gene promoter polymorphism is associated with cervical carcinogenesis ([@b39-ol-0-0-9104]--[@b43-ol-0-0-9104]). Moreover, the expression of the *FAS/FASL* genes and the CD95-CD95 ligand (FAS/FASL) interaction seem to confer susceptibility to the development of cervical cancer ([@b3-ol-0-0-9104]). However, the present study failed to detect any significant effect of the *FAS* gene SNPs on the risk of cervical cancer or any precancerous lesion. This is in accordance with the results of our previous study in another Greek cohort ([@b3-ol-0-0-9104]). It is possible that ethnic differences in *FAS* gene variability may account for the different results among populations ([@b44-ol-0-0-9104]).

In conclusion, the present study confirms the finidngs of previous reports regarding the role of *SULF1* in the risk of precancerous lesions and cervical cancer. This association may have prognostic and pharmacogenetic implications to precancerous lesions or cervical cancer, as *SULF1* may be considered as a therapeutic target or biomarker ([@b45-ol-0-0-9104],[@b46-ol-0-0-9104]). Our findings need to be replicated in other populations of other ethnic backgrouns and in experimental models, in order to elucidate the possible role of polymorphic variants of the *SULF1* gene in the pathophysiology of mechanism of tumorigenesis.

Not applicable.

Funding
=======

No funding was received.

Availability of data and materials
==================================

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors\' contributions
=======================

Eda and VS were involved in the conceptualization of the study, data curation, formal analysis and investigation, methodology, project administration, resources, software, study supervision, validation, writing of the original draft and writing, reviewing and editing the manuscript. AG, EP, MK, GX, ED, GG and ENK provided the patient blood samples and clinical information, and were involved in data validation, and in the writing, reviewing and editing of the manuscript. DAS and AT were involved in data investigation and validation, as well as in the writing, reviewing and editing of the manuscript. AD was involved in the conceptualization of the study, data curation, formal analysis and investigation, methodology, project administration, resources, software, study supervision, validation, writing of the original draft and writing, reviewing and editing the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
==========================================

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The local Ethics Review Board of the University Hospital of Larissa approved the study protocol. Informed consent was obtained from all individual participants included in the study.

Patient consent for publication
===============================

Not applicable.

Competing interests
===================

The authors declare that they have no competing interests.

SNP

:   single nucleotide polymorphism

FAS

:   Fas cell surface death receptor

TNRC6C

:   trinucleotide repeat containing 6C

TMC8

:   transmembrane channel like 8

DMC1

:   DNA meiotic recombinase 1

DUT

:   deoxyuridine triphosphatase

SULF1

:   sulfatase 1

OAS3

:   2′-5-oligoadenylate synthetase 3

GTF2H4

:   general transcription factor IIH subunit 4

IFNG

:   interferon gamma

HPV

:   human papillomavirus

TMC6

:   transmembrane channel like 6

OR

:   odds ratio

CI

:   confidence interval

TNF

:   tumor necrosis factor

HSPGs

:   heparan sulfate proteoglycans

3′-UTR

:   3′-untranslated region

CD95

:   cluster of differentiation 95

FASL

:   Fas ligand

![SULF1 desulfates HSPGs (A) and blocks the binding of growth factors and their receptors (B). As a result it inhibits the activation of growth factor and the signaling pathways (C).](ol-16-03-3833-g00){#f1-ol-0-0-9104}

###### 

Characteristics of SNPs genotyped in the current study.

  SNP   rs number    Gene          Chromosome   Chromosome position   Minor allele   MAF CEU   MAF in our control group
  ----- ------------ ------------- ------------ --------------------- -------------- --------- --------------------------
    1   rs1800682    *FAS*         10           90739943              C              0.45      0.44
    2   rs2290907    *TNRC6C*      17           76093677              C              0.29      0.16
    3   rs16970849   *TMC8*        17           73645503              A              0.14      0.04
    4   rs5757133    *DMC1*        22           37277781              T              0.23      0.31
    5   rs3784621    *DUT*         15           46420384              C              0.46      0.20
    6   rs4737999    *SULF1*       8            70680589              A              0.20      0.27
    7   rs9893818    *TMC8/TMC6*   17           73653762              A              0.04      0.00
    8   rs12302655   *OAS3*        12           111858889             A              0.13      0.00
    9   rs2894054    *GTF2H4*      6            30980253              T              0.09      0.12
  10    rs11177074   *IFNG*        12           66830701              C              0.14      0.07

SNP, single nucleotide polymorphism; MAF, minor allele frequency; CEU, Utah residents with Northern and Western European ancestry; *FAS*, Fas cell surface death receptor; *TNRC6C*, trinucleotide repeat containing 6C; *TMC8*, transmembrane channel like 8; *DMC1*, DNA meiotic recombinase 1; *DUT*, deoxyuridine triphosphatase; *SULF1*, sulfatase 1; *OAS3*, 2--5-oligoadenylate synthetase 3; *IFNG*, interferon gamma.

###### 

Genotype call rate and exact test for HWE of each SNP in the current study.

                                          Exact test (P-value) for HWE   
  ---- ------------ ------------- ------- ------------------------------ ------
  1    rs1800682    *FAS*         99.18   0.096                          1
  2    rs2290907    *TNRC6C*      99.67   0.83                           0.36
  3    rs16970849   *TMC8*        99.34   1                              1
  4    rs5757133    *DMC1*        98.85   0.14                           0.11
  5    rs3784621    *DUT*         99.34   0.85                           0.6
  6    rs4737999    *SULF1*       99.34   0.29                           0.12
  7    rs9893818    *TMC8/TMC6*   99.34   NA                             NA
  8    rs12302655   *OAS3*        99.84   1                              1
  9    rs2894054    *GTF2H4*      99.67   0.089                          0.78
  10   rs11177074   *IFNG*        98.85   0.38                           0.71

SNP, single nucleotide polymorphism; HWE, Hardy-Weinberg Equilibrium; NA, non-available; *FAS*, Fas cell surface death receptor; *TNRC6C*, trinucleotide repeat containing 6C; *TMC8*, transmembrane channel like 8; *DMC1*, DNA meiotic recombinase 1; *DUT*, deoxyuridine triphosphatase; *SULF1*, sulfatase 1; *OAS3*, 2--5-oligoadenylate synthetase 3; *IFNG*, interferon gamma.

###### 

Allelic and genotype frequencies of SNPs in healthy controls and in cases (cervical cancer cases, cases with low grade and with high grade precancerous lesions).

  SNP          Genotypes/alleles   Controls n (%)   All cases n (%)   Cervical cancer n (%)   High-grade precancerous lesions, n (%)   Low-grade precancerous lesions, n (%)
  ------------ ------------------- ---------------- ----------------- ----------------------- ---------------------------------------- ---------------------------------------
  rs1800682                                                                                                                            
    Genotype   C/C                 63 (22)          49 (16)           2 (12)                  13 (13)                                  34 (17)
               T/C                 129 (44)         150 (48)          8 (47)                  50 (51)                                  92 (47)
               T/T                 98 (34)          114 (36)          7 (41)                  36 (36)                                  71 (36)
               Missed              2                3                 0                       1                                        2
    Allele     T                   325 (56)         378 (60)          22 (65)                 122 (62)                                 234 (59)
               C                   255 (44)         248 (40)          12 (35)                 76 (38)                                  160 (41)
  rs2290907                                                                                                                            
    Genotype   C/C                 8 (3)            4 (1)             1 (6)                   1 (1)                                    2 (01)
               T/C                 79 (27)          81 (26)           3 (0.18)                19 (0.19)                                59 (0.30)
               T/T                 204 (70)         230 (73)          13 (0.76)               80 (0.80)                                137 (0.69)
               Missed              1                1                 0                       0                                        1
    Allele     T                   487 (84)         541 (86)          29 (85)                 179 (90)                                 333 (84)
               C                   95 (16)          89 (14)           5 (15)                  21 (10)                                  63 (16)
  rs16970849                                                                                                                           
    Genotype   G/A                 24 (8)           30 (10)           0 (0)                   10 (10)                                  20 (10)
               G/G                 265 (92)         285 (90)          17 (100)                90 (90)                                  178 (90)
               A/A                 0 (0)            0 (0)             0 (0)                   0 (0)                                    0 (0)
               Missed              3                1                 0                       0                                        1
    Allele     G                   554 (96)         600 (95)          34 (100)                190 (95)                                 376 (95)
               A                   24 (4)           30 (5)            0 (0)                   10 (5)                                   20 (5)
  rs5757133                                                                                                                            
    Genotype   C/C                 142 (49)         156 (50)          11 (65)                 45 (45)                                  100 (51)
               C/T                 114 (39)         120 (39)          5 (29)                  43 (43)                                  72 (37)
               T/T                 34 (12)          35 (0.11)         1 (6)                   11 (11)                                  23 (12)
               Missed              2                5                 0                       1                                        4
    Allele     C                   398 (69)         432 (69)          27 (79)                 133 (67)                                 272 (70)
               T                   182 (31)         190 (31)          7 (21)                  65 (33)                                  118 (30)
  rs3784621                                                                                                                            
    Genotype   C/C                 12 (4)           14 (4)            2 (12)                  3 (3)                                    9 (5)
               T/C                 92 (32)          97 (31)           4 (25)                  30 (30)                                  63 (32)
               T/T                 187 (64)         202 (65)          10 (62)                 66 (67)                                  126 (64)
               Missed              1                3                 1                       1                                        1
    Allele     T                   466 (80)         501(80)           24 (75)                 162 (82)                                 315 (80)
               C                   116 (20)         125 (20)          8 (25)                  36 (18)                                  81 (20)
  rs4737999                                                                                                                            
    Genotype   A/A                 24 (8)           13 (4)            1 (6)                   6 (6)                                    6 (3)
               G/A                 106 (37)         125 (40)          7 (41)                  37 (37)                                  81 (41)
               G/G                 160 (55)         176 (56)          9 (53)                  57 (57)                                  110 (56)
               Missed              2                2                 0                       0                                        2
    Allele     G                   426 (73)         477 (76)          25 (74)                 151 (76)                                 301 (76)
               A                   154 (27)         151 (24)          9 (26)                  49 (24)                                  93 (24)
  rs9893818                                                                                                                            
    Genotype   C/C                 290 (100)        316 (100)         17 (100)                100 (100)                                197 (100)
               C/A                 0 (0)            0 (0)             0 (0)                   0 (0)                                    0 (0)
               A/A                 0 (0)            0 (0)             0 (0)                   0 (0)                                    0 (0)
               Missed              2                2                 0                       0                                        2
    Allele     C                   580 (100)        628 (100)         34 (100)                200 (100)                                394 (100)
               A                   0 (0)            0 (0)             0 (0)                   0 (0)                                    0 (0)
  rs12302655                                                                                                                           
    Genotype   G/G                 292 (100)        313 (99)          17 (100)                99 (99)                                  197 (99)
               G/A                 0 (0)            2 (1)             0 (0)                   1 (1)                                    1 (1)
               A/A                 0 (0)            0 (0)             0 (0)                   0 (0)                                    0 (0)
               Missed              0                1                 0                       0                                        1
    Allele     G                   584 (100)        628 (99.7)        34 (100)                199 (100)                                395 (100)
               A                   0 (0)            2 (0.3)           0 (0)                   1 (0)                                    1 (0)
  rs2894054                                                                                                                            
    Genotype   C/C                 229 (79)         246 (78)          17 (100)                78 (78)                                  151 (76)
               C/T                 54 (19)          67 (21)           0 (0)                   22 (22)                                  45 (23)
               T/T                 7 (02)           3 (1)             0 (0)                   0 (0)                                    3 (2)
               Missed              2                0                 0                       0                                        0
    Allele     C                   512 (88)         559 (88)          34 (100)                178 (89)                                 347 (87)
               T                   68 (12)          73 (12)           0 (0)                   22 (11)                                  51 (13)
  rs11177074                                                                                                                           
    Genotype   C/C                 0 (0)            1 (0)             0 (0)                   0 (0)                                    1 (1)
               T/C                 42 (15)          52 (17)           3 (18)                  18 (18)                                  31 (16)
               T/T                 245 (85)         261 (83)          14 (82)                 81 (0.82)                                166 (84)
               Missed              5                2                 0                       1                                        1
    Allele     T                   532 (93)         574 (91)          31 (91)                 180 (0.91)                               363 (92)
               C                   42 (7)           54 (9)            3 (9)                   18 (9)                                   33 (8)

SNPs, single nucleotide polymorphisms. The rows indicating the 'missed' numbers indicate the number of failed samples (DNA from some participants failed to be genotyped and consequently there were a few missed genotypes). Percentages (%) have been calculated according to the total number of patients in each group.

###### 

Single locus analysis.

                           All cases (n=316) vs. controls (n=292)   Low-grade (n=199) vs. controls (n=292)   High-grade (n=100) vs. controls (n=292)   Cancer (n=17) vs. controls (n=292)                                                    
  -------------- --------- ---------------------------------------- ---------------------------------------- ----------------------------------------- ------------------------------------ ------------------- ------- -------------------- -------
  rs1800682                                                                                                                                                                                                                                  
    Codominant   T/T       1.00                                     0.16                                     1.00                                      0.47                                 1.00                0.15    1.00                 0.54
                 T/C       1.00 (0.70--1.43)                                                                 0.98 (0.66--1.48)                                                              1.06 (0.64--1.74)           0.87 (0.30--2.48)    
                 C/C       0.67 (0.42--1.06)                                                                 0.74 (0.44--1.25)                                                              0.56 (0.28--1.14)           0.44 (0.09--2.21)    
    Recessive    T/T-T/C   1.00                                     0.056                                    1.00                                      0.22                                 1.00                0.054   1.00                 0.84
                 C/C       0.67 (0.44--1.01)                                                                 0.75 (0.47--1.19)                                                              0.54 (0.29--1.04)           0.48 (0.11--2.16)    
  rs2290907                                                                                                                                                                                                                                  
    Codominant   T/T       1.00                                     0.37                                     1.00                                      0.33                                 1.00                0.12    1.00                 0.57
                 T/C       0.91 (0.63--1.31)                                                                 1.11 (0.74--1.66)                                                              0.61 (0.35--1.08)           0.60 (0.17--2.15)    
                 C/C       0.44 (0.13--1.49)                                                                 0.37 (0.08--1.78)                                                              0.32 (0.04--2.59)           1.96 (0.23--16.89)   
    Recessive    T/T-T/C   1.00                                     0.19                                     1.00                                      0.16                                 1.00                0.27    1.00                 0.51
                 C/C       0.45 (0.14--1.53)                                                                 0.36 (0.08--1.72)                                                              0.36 (0.04--2.89)           2.21 (0.26--18.77)   
  rs16970849                                                                                                                                                                                                                                 
                 G/G       1.00                                     0.6                                      1.00                                      0.5                                  1.00                0.61    1.00                 0.091
                 G/A       1.16 (0.66--2.04)                                                                 1.24 (0.67--2.31)                                                              1.23 (0.56--2.66)           0.00 (0.00-NA)       
  rs5757133                                                                                                                                                                                                                                  
    Codominant   C/C       1.00                                     0.95                                     1.00                                      0.86                                 1.00                0.77    1.00                 0.42
                 T/C       0.96 (0.68--1.35)                                                                 0.90 (0.61--1.33)                                                              1.19 (0.73--1.93)           0.57 (0.19--1.68)    
                 T/T       0.94 (0.55--1.58)                                                                 0.96 (0.53--1.73)                                                              1.02 (0.48--2.18)           0.38 (0.05--3.04)    
    Recessive    C/C-T/C   1.00                                     0.86                                     1.00                                      0.98                                 1.00                0.87    1.00                 0.42
                 T/T       0.95 (0.58--1.58)                                                                 1.01 (0.57--1.77)                                                              0.94 (0.46--1.94)           0.47 (0.06--3.66)    
  rs3784621                                                                                                                                                                                                                                  
    Codominant   T/T       1.00                                     0.97                                     1.00                                      0.97                                 1.00                0.84    1.00                 0.4
                 T/C       0.98 (0.69--1.38)                                                                 1.02 (0.69--1.50)                                                              0.92 (0.56--1.52)           0.81 (0.25--2.66)    
                 C/C       1.08 (0.49--2.39)                                                                 1.11 (0.46--2.72)                                                              0.71 (0.19--2.59)           3.12 (0.61--15.85)   
    Recessive    T/T-T/C   1.00                                     0.83                                     1.00                                      0.82                                 1.00                0.62    1.00                 0.19
                 C/C       1.09 (0.49--2.39)                                                                 1.11 (0.46--2.68)                                                              0.73 (0.20--2.63)           3.32 (0.68--16.29)   
  rs4737999                                                                                                                                                                                                                                  
    Codominant   G/G       1.00                                     0.096                                    1.00                                      **0.042**                            1.00                0.75    1.00                 0.89
                 G/A       1.07 (0.77--1.50)                                                                 1.11 (0.76--1.62)                                                              0.98 (0.61--1.59)           1.17 (0.42--3.25)    
                 A/A       0.49 (0.24--1.00)                                                                 **0.36 (0.14--0.92)**                                                          0.70 (0.27--1.80)           0.74 (0.09--6.11)    
    Recessive    G/G-G/A   1.00                                     **0.033**                                1.00                                      **0.014**                            1.00                0.45    1.00                 0.71
                 A/A       **0.48 (0.24--0.96)**                                                             **0.35 (0.14--0.87)**                                                          0.71 (0.28--1.78)           0.69 (0.09--5.45)    
  rs9893818                NA                                                                                NA                                                                             NA                          NA                   
  rs12302655                                                                                                                                                                                                                                 
                 G/G       1.00                                     0.1                                      1.00                                      0.18                                 1.00                0.098   NA                   NA
                 G/A       NA (0.00-NA)                                                                      NA (0.00-NA)                                                                   NA (0.00-NA)                NA                   
  rs2894054                                                                                                                                                                                                                                  
    Codominant   C/C       1.00                                     0.28                                     1.00                                      0.46                                 1.00                0.1     1.00                 0.02
                 T/C       1.15 (0.77--1.72)                                                                 1.26 (0.81--1.97)                                                              1.20 (0.68--2.09)           0.00 (0.00-NA)       
                 T/T       0.40 (0.10--1.56)                                                                 0.65 (0.17--2.55)                                                              0.00 (0.00-NA)              0.00 (0.00-NA)       
    Recessive    C/C-T/C   1.00                                     0.15                                     1.00                                      0.48                                 1.00                0.041   1.00                 0.37
                 T/T       0.39 (0.10--1.51)                                                                 0.62 (0.16--2.42)                                                              0.00 (0.00-NA)              0.00 (0.00-NA)       
  rs11177074                                                                                                                                                                                                                                 
    Codominant   T/T       1.00                                     0.42                                     1.00                                      0.39                                 1.00                0.41    1.00                 0.74
                 T/C       1.16 (0.75--1.81)                                                                 1.09 (0.66--1.80)                                                              1.30 (0.71--2.38)           1.25 (0.34--4.54)    
                 C/C       NA (0.00-NA)                                                                      NA (0.00-NA)                                                                   NA                          NA                   
    Recessive    T/T-T/C   1.00                                     0.25                                     1.00                                      0.18                                 NA                  NA      NA                   NA
                 C/C       NA (0.00-NA)                                                                      NA (0.00-NA)                                                                   NA                          NA                   

SNP, single nucleotide polymorphism; CI, confidence interval; OR, odds ratio. Statistically significant values are shown in bold; NA, not available.

[^1]: Contributed equally
